Peptide Therapy Consultation in Frisco, TX

At a glance

What this session offers

A plain description of what is in the bag and what happens while you are here.

An honest conversation

We will walk you through current regulatory status, the state of the research, and the specific risks — including the ones that make this unsuitable for some people.

Anti-doping guidance

If you compete under WADA or NCAA rules, we will tell you plainly what that means for you.

Clinical context

A chance to discuss your actual injury or recovery situation with a clinician, including alternatives that have better evidence.

No obligation

Consultations are exactly that.

The science

What the research actually shows

We would rather tell you where the evidence is strong, where it is thin, and where it simply does not exist yet.

Regulatory status first, because it matters most

Neither BPC-157 nor TB-500 is an FDA-approved drug, and neither is a lawful dietary supplement ingredient. Neither is currently on the FDA 503A Bulks List, which means neither is presently eligible for lawful pharmacy compounding. Most material sold online carries 'research use only' disclaimers and is made outside regulatory oversight, with real risk of misidentification, contamination and inaccurate dosing.

What has changed recently

BPC-157 was previously in Category 2 of the FDA's bulks review — substances that may present significant safety risks. On 15 April 2026 the FDA removed BPC-157, TB-500 and ten other peptides from Category 2 because the nominations were withdrawn; removal is not approval and does not make them eligible for compounding. At the Pharmacy Compounding Advisory Committee meeting of 23-24 July 2026, FDA's own scientists recommended against all seven peptides reviewed, while the committee voted narrowly in favour of including BPC-157 and TB-500. That recommendation is non-binding and the FDA has not acted on it.

The proposed mechanisms, accurately described

BPC-157 is a synthetic pentadecapeptide derived from a sequence found in human gastric juice; proposed mechanisms include promoting angiogenesis via VEGFR2 activation and modulating the nitric oxide system. TB-500 is a synthetic fragment of thymosin beta-4, an actin-sequestering protein, with proposed roles in actin regulation, cell migration and angiogenesis. These mechanisms come from animal and in-vitro studies. There are no adequate, well-controlled human trials establishing safety or efficacy for tendon, ligament, gut or joint healing in people.

Two risks worth stating plainly

Long-term human safety is unknown, and a specific theoretical concern follows from the proposed mechanism: agents that promote angiogenesis and cell proliferation have not been shown to be safe in people with occult or existing malignancy. Separately, WADA prohibits BPC-157 and TB-500 at all times, in and out of competition, and sanctions have been imposed — a Canadian athlete received a four-year ban for these compounds.

Who commonly considers this: Athletes and active adults exploring recovery options who want the regulatory and evidence picture before making a decision.

Safety, screening & contraindications

Not FDA-approved. Not currently eligible for lawful compounding. No claim to heal, repair, treat or accelerate recovery is supportable by the current evidence.
Evidence is preclinical — animal and in-vitro studies. Long-term human safety is unknown.
Prohibited in sport by WADA at all times, in and out of competition, with four-year sanctions imposed in reported cases.
Not appropriate for anyone with a current or suspected malignancy, given the proposed proliferative and angiogenic mechanisms.

References

Peptide Therapy Consultation